Purdue Pharma Announces Plans to Fund Investigator-Initiated Research to Evaluate Strategies for Optimal Opioid Sparing, Tapering and Discontinuation

Deadline to submit letter of intent is Fri, Sept. 30, 2016

STAMFORD, Conn. – Sept. 2, 2016 – Purdue Pharma L.P. has issued a request for proposals (RFP) to fund investigator-initiated research to evaluate strategies for optimal opioid sparing, tapering and discontinuation. When pain is severe, but short lived – for example, after many surgeries – starting and stopping therapy with opioid analgesics may be reasonably straightforward. However, in the setting of chronic pain, tapering doses of opioid analgesics or stopping them all together can be complex and there is little data to guide the approach. These represent important data gaps for optimizing medical treatment to adequately and safely control chronic pain.

“Opioid analgesics are the right choice for many patients but, opioids are also associated with risks that can be very serious. Given the severity of many of these risks, health care professionals regularly monitor, and try to taper the dose, sometimes by using opioid-sparing treatments. There is little data to help doctors with this,” said Gail Cawkwell, M.D., Ph.D., Chief Medical Officer, Purdue Pharma. “We hope qualified researchers will be eager to apply for funds to perform high quality research to address this important data gap.”

Qualified U.S. researchers interested in conducting studies to answer this important question are encouraged to apply. The deadline to submit a letter of intent must be submitted via email to iitprogram@pharma.com by 5 p.m. EDT on Fri, Sept. 30, 2016.

For detailed proposal submission instructions and other pertinent information, please visit http://www.purduepharma.com/healthcare-professionals/clinical-trials/investigator-initiated-research/.


About Purdue Pharma L.P.

Purdue Pharma is a privately-held pharmaceutical company and is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The company’s leadership and employees are committed to serving healthcare professionals, patients and caregivers quality products and educational resources to support their proper use. Purdue Pharma is engaged in the research, development, production and distribution of both prescription and over-the-counter medicines and hospital products. With Purdue Pharma’s expertise in drug development, commercialization, and life-cycle management, the company is diversifying in high-need areas to expand through strategic acquisitions and creative partnerships. For more information please visit www.purduepharma.com or follow the company on LinkedIn, Instagram, Twitter and YouTube.

 

# # #

Media Inquiries:

Catherine London
Corporate Communications
Purdue Pharma L.P.
203-588-7530
catherine.london@pharma.com

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.